Treatment for cats with hypertrophic cardiomyopathy (HCM/HOCM) and stage C congestive heart failure (CHF)
The SATH is taking part in a multi-centre clinical study researching an investigational medicinal product to treat cats with diagnosed HCM/HOCM and previous CHF. If you’re one of our referring vets we’d like to ask you to please inform cat owners about this clinical study.
Overview of the study
The study duration is up to 4.5 years. It is a double-blind, placebo-controlled study in which cat owners administer a liquid solution to their pets orally once daily. The goal of the study is to prolong the life of the cats. ALL cats in the study will receive standard of care according to the guidelines of the American College of Veterinary Internal Medicine (ACVIM).
Requirements for patients
- Primary cardiomyopathy (HCM/HOCM) and CHF in the past 60 days
- A limited number of other phenotypes are also permitted
- Clinically stable
This is not an exhaustive list. Contact the SATH Cardiology service if you have any questions.
Free care
All of the services required as part of the study are covered by the study sponsor, including:
- Examinations of the heart and respiratory tract
- Diagnostic tests including echocardiograms, X-rays of the chest and systolic blood pressure
- Blood and urine tests including haematology, biochemistry, total thyroxine, fructosamine, NT-proBNP and cTnI
How to refer patients
It's easy to refer your patients. To get more information, just contact the SATH Cardiology service and mention the cat study.